Walgreens Boots Alliance, Inc. (WBA) EBITDA Margin: -7.64%
Is Walgreens Boots Alliance, Inc.’s EBITDA margin high or low?
Walgreens Boots Alliance, Inc.'s EBITDA margin of -7.64% is 595% below its 5-year average of 1.54%, near the low end of its 5-year range (-7.64%–5.84%).
As of Friday, June 19, 2026. 60.84% below its 12-month average of -4.75%.
WBA EBITDA Margin Chart
WBA Average EBITDA Margin Chart
WBA Current vs Average EBITDA Margin Chart
WBA EBITDA Margin Metrics
EBITDA MARGIN
-7.64%
EBITDA MARGIN AVG TTM
-4.75%
EBITDA MARGIN AVG 3Y
-0.21%
EBITDA MARGIN AVG 5Y
1.54%
EBITDA MARGIN AVG 10Y
3.72%
EBITDA MARGIN AVG 15Y
6.08%
EBITDA MARGIN AVG 20Y
6.45%
CURRENT VS TTM AVG
-60.84%
CURRENT VS 3Y AVG
-3626.83%
CURRENT VS 5Y AVG
-595.03%
CURRENT VS 10Y AVG
-305.43%
CURRENT VS 15Y AVG
-225.63%
CURRENT VS 20Y AVG
-218.42%
WBA Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Walgreens Boots Alliance, Inc. (WBA) | $10.37B | -7.64% | -4.75% | -0.21% | 1.54% |
| Baxter International Inc. (BAX)vs › | $10.27B | 6.81% | 8.65% | 4.13% | 9.00% |
| Revvity, Inc. (RVTY)vs › | $11.16B | 23.20% | 26.85% | 28.84% | 31.56% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.91B | 10.23% | 12.29% | 18.59% | 20.64% |
| Tempus AI, Inc. (TEM)vs › | $8.87B | -17.48% | -52.76% | -51.11% | -63.28% |
| Hims & Hers Health, Inc. (HIMS)vs › | $7.91B | 7.60% | 6.80% | 0.29% | -7.92% |
| The Cooper Companies, Inc. (COO)vs › | $12.85B | 25.74% | 26.63% | 26.11% | 26.16% |
| Align Technology, Inc. (ALGN)vs › | $13.04B | 18.98% | 19.70% | 20.24% | 21.46% |
| Solventum Corporation (SOLV)vs › | $13.06B | 30.62% | 24.56% | 26.05% | 27.07% |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.64B | 48.39% | -17.53% | -54.94% | 28.49% |
Margin Comparison
Gross Margin
17.1%
EBITDA Margin
-7.6%
Operating Margin
-2.0%
Net Margin
-4.1%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Walgreens Boots Alliance, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Walgreens Boots Alliance, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The EBITDA margin for WBA stock is -7.64%.
- Is Walgreens Boots Alliance, Inc.'s EBITDA margin high or low?
- Walgreens Boots Alliance, Inc.'s EBITDA margin of -7.64% is 595% below its 5-year average of 1.54%, near the low end of its 5-year range (-7.64%–5.84%).
- What is the TTM average EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The TTM average EBITDA margin for WBA stock is -4.75%.
- What is the 3Y average EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The 3Y average EBITDA margin for WBA stock is -0.21%.
- What is the 5Y average EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The 5Y average EBITDA margin for WBA stock is 1.54%.
- What is the 10Y average EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The 10Y average EBITDA margin for WBA stock is 3.72%.
- What is the 15Y average EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The 15Y average EBITDA margin for WBA stock is 6.08%.
- What is the 20Y average EBITDA margin for Walgreens Boots Alliance, Inc. (WBA)?
- The 20Y average EBITDA margin for WBA stock is 6.45%.
Walgreens Boots Alliance, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2024-08-31 | -7.64% |
| 2023-08-31 | -1.86% |
| 2022-08-31 | 3.97% |
| 2021-08-31 | 4.71% |
| 2020-08-31 | 4.24% |
| 2019-08-31 | 5.84% |
| 2018-08-31 | 5.83% |
| 2017-08-31 | 5.88% |
| 2016-08-31 | 6.76% |
| 2015-08-31 | 6.53% |
| 2014-08-31 | 6.65% |
| 2013-08-31 | 7.39% |
| 2012-08-31 | 6.46% |
| 2011-08-31 | 7.55% |
| 2010-08-31 | 6.66% |
| 2009-08-31 | 6.67% |
| 2008-08-31 | 7.25% |
| 2007-08-31 | 7.12% |
| 2006-08-31 | 6.91% |
| 2005-08-31 | 6.89% |
| 2004-08-31 | 6.79% |
| 2003-08-31 | 6.79% |
| 2002-08-31 | 6.73% |
| 2001-08-31 | 6.77% |
| 2000-08-31 | 6.86% |
| 1999-08-31 | 6.87% |
| 1998-08-31 | 6.70% |
| 1997-08-31 | 6.53% |
| 1996-08-31 | 6.38% |
| 1995-08-31 | 6.27% |
Related Metrics
About Walgreens Boots Alliance, Inc.
Walgreens Boots Alliance, Inc., established in 1901 and based in Deerfield, Illinois, operates as a leading global retailer focused on pharmacy, health, and beauty products. Its business activities are organized into two primary divisions: the United States and International. In the United States, the company dispenses prescription drugs and offers a diverse selection of retail goods. This includes items for health, wellness, beauty, and personal care, alongside general merchandise and consumable products, all available through its extensive network of retail drugstores. The U.S. segment also provides specialized central pharmacy services and mail delivery options for prescriptions. As of August 31, 2021, this division managed 8,965 retail outlets under the Walgreens and Duane Reade banners, complemented by five specialty pharmacies. The International segment focuses on the sale of prescription medications, health and wellness items, beauty products, personal care essentials, and other consumer goods. These are sold through its pharmacy-centric health and beauty retail locations, optical practices, its online platform boots.com, and an integrated mobile application. Additionally, this segment engages in pharmaceutical wholesale and distribution operations within Germany. By August 31, 2021, the international portfolio included 4,031 retail stores operating under brands such as Boots, Benavides, and Ahumada, located across countries including the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile. It also oversaw 548 optical practices, with 160 of these operating as franchises.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Timothy C. Wentworth